Business Context and Reporting Period
This Form 8-K, dated December 13, 2024, is a Current Report filed by First Busey Corporation (Busey) regarding its proposed merger with CrossFirst Bankshares, Inc. (CrossFirst). The filing serves as a supplement to the joint proxy statement/prospectus previously filed with the SEC. The primary purpose is to disclose additional information in response to two shareholder lawsuits and demand letters alleging false or misleading disclosures regarding the merger.
Key Financial Metrics and Transaction Details
The filing does not report standard quarterly financial metrics such as revenue, net income, or cash flow for the reporting period. Instead, it provides specific valuation multiples and accretion/dilution estimates related to the merger transaction:
- Merger Accretion/Dilution: The transaction is estimated to be accretive to Busey's 2026 EPS by 16.2% and dilutive to Busey's tangible book value per share by 0.6% (assuming closing as of March 31, 2025).
- Valuation Multiples (CrossFirst Selected Companies): Price-to-tangible book value ranged from 0.81x to 2.64x; 2024 estimated EPS multiples ranged from 8.7x to 19.5x; 2025 estimated EPS multiples ranged from 9.0x to 18.9x.
- Valuation Multiples (Busey Selected Companies): Price-to-tangible book value ranged from 0.92x to 3.99x; 2024 estimated EPS multiples ranged from 10.6x to 18.1x; 2025 estimated EPS multiples ranged from 10.7x to 17.9x.
- Transaction Multiples (Selected Transactions): Price-to-tangible book value ranged from 0.97x to 2.02x; Price per share to LTM EPS ranged from 6.5x to 16.4x.
- Discount Rates: The Dividend Discount Model analyses utilized discount rates ranging from 11.0% to 13.0%.
- Advisor Fees: KBW received approximately $750,000 from CrossFirst for its role in the November 2022 acquisition of Farmers & Stockmens Bank.
Material Changes and Litigation
The filing details significant legal developments affecting the merger timeline and disclosure requirements:
- Shareholder Litigation: Two lawsuits were filed in the District Court of Johnson County, Kansas: Joel Zalvin v. CrossFirst Bankshares, Inc., et al. (filed November 26, 2024) and Stephen Bushansky v. CrossFirst Bankshares, Inc., et al. (filed November 29, 2024).
- Allegations: The complaints and related demand letters allege violations of Section 14(a) and Section 20(a) of the Securities Exchange Act of 1934, Rule 14a-9, and breaches of fiduciary duties under state law. Plaintiffs claim the registration statement was false and misleading.
- Company Response: Busey and CrossFirst deny all allegations, stating the claims are without merit. However, to avoid delays and minimize litigation risks, the companies are voluntarily supplementing the proxy statement with additional disclosures regarding the transaction committee formation and valuation analyses.
Guidance, Outlook, and Risks
The filing contains extensive forward-looking statements regarding the merger's expected benefits, including cost savings, synergies, and accretion to earnings. Management emphasizes that actual results may differ materially due to various risks:
- Transaction Risks: The merger may not close if regulatory or stockholder approvals are not obtained, or if conditions are not satisfied. Regulatory approvals may impose conditions that adversely affect the combined company.
- Integration Risks: Anticipated synergies may not be realized, and integration may be more difficult, time-consuming, or costly than expected.
- Market and Economic Risks: Risks include changes in interest rates, prepayment rates, loan portfolio concentrations (specifically commercial real estate), and general economic conditions.
- Operational Risks: Potential loss of key personnel, customers, or suppliers; cybersecurity breaches; and increased competition from non-bank entities.
- Legal Risks: The outcome of the pending litigation could impact the transaction or result in unexpected costs.
Investor Verification Checklist
- Verify the status of the two shareholder lawsuits (Zalvin and Bushansky) and any potential impact on the merger closing date.
- Review the full joint proxy statement/prospectus to understand the complete context of the supplemental disclosures regarding the CrossFirst transaction committee and valuation methodologies.
- Confirm the regulatory approval status required for the merger to proceed.
- Assess the sensitivity of the 16.2% EPS accretion and 0.6% tangible book value dilution estimates to changes in interest rates and integration costs.
- Monitor for any additional demand letters or complaints from other stockholders as noted in the filing.